While the rest of the market was on a tear, Whole Foods' stock has fallen, as much as 41% if you bought at the peak. Instead of telling you why you should hold your shares -- I have no intention to sell mine -- I want to share an investing parallel from almost 40 years ago. A little context about the importance of patience and time will serve us all well in the interim.
Let's talk about The Coca-Cola Company, and 1975.
Selling the world a Coke, but Mr. Market wasn't buying it
Back in the '70s, Coca-Cola was already all over the world, but it was still relatively early in its expansion. Most of the world was much poorer than today, and consumer goods like Coca-Cola weren't either affordable or readily available to the masses.
Top 10 Blue Chip Companies To Invest In 2015: Pazoo Inc (PZOO)
Pazoo, Inc., formerly IUCSS, Inc., incorporated on November 16, 2010, is a development-stage company. The Company is an online retailer and distributer of nutritional foods/supplements, wellness goods, and fitness apparel.
As of December 31, 2011, the Company�� source of revenue was through www.pazoo.com. The Company offers a range of products through various catalogs, such as health and beauty, vitamins and supplements, apparel, accessories, food and beverages, fitness and sports equipments, gifts, videos and books, and pet wellness.
Advisors' Opinion:- [By Bryan Murphy]
For those traders who were lucky and smart enough to be in an Arotech Corporation (NASDAQ:ARTX) before today, then congratulations - you're up at least 38% on your position. Now it's time to get out. Conversely, if you're looking for a new name to get into (or perhaps looking for a place to park your ARTX proceeds), then you may want to consider Pazoo Inc. (OTCBB:PZOO)... a tiny online retailer of health and fitness goods. PZOO has dropped several tell-tale hints that more upside is on the way.
5 Best Net Payout Yield Stocks To Invest In Right Now: POSCO(PKX)
POSCO engages in the manufacture and sale of steel products in South Korea and internationally. The company offers hot rolled steel for general structures, gas cylinders, hull structures, automobile structural uses, and machine structures; atmospheric corrosion resistant steel; steel for casting and tubing of oilwell pipes; steel for line pipes; and general machine structural steel, alloy steel, and steel for tools and machine parts, as well as steel for ships. It also provides cold rolled, galvanized, electrical, and stainless steel products, as well as titanium products. In addition, it involves in various activities, including engineering and construction, steel work maintenance and machinery installation, computer hardware and software distribution, economic research and consulting, rare and special metals manufacturing, rental houses construction and management, energy and resource development, architecture and consulting, electronic commerce, refractories manufacturi ng and sales, transporting and warehousing, and electricity generation. Further, the company engages in components manufacturing and sales, ferromanganese manufacturing, financial investment, LED lightning, coal trading, mine development, finance, iron ore mining and trading, harbor loading and unloading, spinning and weaving, and paper and cement manufacturing businesses; operates athletic facilities and a distribution center; and invests in venture companies and biotech ventures. POSCO was founded in 1968 and is based in Seoul, South Korea.
Advisors' Opinion:- [By Jeff Reeves]
Other options include Korean steel giant Posco (PKX), though admittedly this is much more of a global player and subject to commodity trends instead of South Korean growth.
- [By Jake Maxwell Watts]
Markets in Korea were higher for the seventh straight session, after a break for Christmas. The Kospi (KR:SEU) �was up 0.1%, near its highest levels in over three weeks. Index heavyweights Samsung Electronics Co. (KR:005930) � (SSNLF) �lost 0.1%, while steel producer Posco (KR:005490) � (PKX) �and auto manufacturer Kia Motors Co. (KR:000270) � (KIMTF) �gained 1.1% and lost 0.2%, respectively.
5 Best Net Payout Yield Stocks To Invest In Right Now: Hospira Inc (HSP)
Hospira, Inc. (Hospira), incorporated on September 16, 2003, is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira's portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa, and the APAC segment includes Asia, Japan, Australia and New Zealand. In all segments, Hospira sells a line of products, including specialty injectable and other pharmaceuticals and medication management products.
Specialty Injectable Pharmaceuticals
Hospira's specialty injectable pharmaceutical products consist of generic injectable pharmaceuticals. The other drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. All of Hospira's generic injectable pharmaceuticals in the United States include unit-of-use bar-code labels that can be used to support medication delivery. Hospira primarily procures the active pharmaceutical ingredients in these products from third-party suppliers. During the year ended December 31, 2011, Hospira portfolio included 87 injectable drug launches consisting of 13 compounds. Among these launches included, in the United States, docetaxel (an oncolytic drug used to treat a variety of cancers), topotecan (an oncolytic drug used for the treatment of small cell lung cancer) and imipenem-cilastatin (a beta-lactam antibiotic). Hospira also launched a solution formulation of gemcitabine (an oncolytic drug used to treat a variety of cancers), which augmented Hospira's portfolio of gemcitabin! e products. New-to-country launches in EMEA in 2011, included topotecan, meropenem, gemcitabine, imipenem-cilastatin, remifentanil, docetaxel and levofloxacin. New-to-country launches in APAC in 2011, included docetaxel, piperacillin tazobactam, oxaliplatin, meropenem and gemcitabine. Hospira's specialty injectable pharmaceutical products also include Precedex (dexmedetomidine HCl), a sedative. Precedex is licensed to Hospira by Orion Corporation in the Americas and APAC segments, and in the Middle East and Africa.
Hospira sells and markets Precedex for use in non-intubated patients requiring sedation, as well as intubated and mechanically ventilated patients. Hospira's specialty injectable pharmaceuticals also include biologic products, which are molecules derived from cells that are demonstrated to be similar to an approved originator product. Hospira's biosimilar, Retacrit, was available in 20 EMEA countries during 2011. Its second biosimilar, Nivestim, was launched during the year ended December 31, 2010, and was available in 21 countries, including Australia, where the biosimilar filgrastim product was launched in 2011. Hospira's drug delivery formats include offerings in ampules and flip-top vials, which clinicians can use with standard syringes. Hospira's drug delivery options include Carpuject and iSecure prefilled syringes, AnsyrTM prefilled needleless emergency syringe systems, First Choice ready-to-use premix and the ADD-Vantage system for preparing drug solutions from prepackaged drug powders or concentrates.
Other Pharmaceuticals
Hospira's other pharmaceuticals primarily consist of intravenous (I.V.) solutions, nutritionals and contract manufacturing services. Hospira offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. All of Hospira's injectable I.V. solutions in the United States include unit-of-use bar-c! ode label! s that can be used to support medication management efforts. Hospira also offers infusion therapy solutions in its VisIV non-PVC, non-DEHP I.V. container, an I.V. bag. Hospira's contract manufacturing services are offered through its One2One services group, which provides formulation development, filling and finishing of injectable and oral drugs worldwide. Hospira works with its pharmaceutical and biotechnology customers to develop injectable forms of their drugs, and Hospira fills and finishes those and other drugs into containers and packaging selected by the customer. The customer then sells the finished products under its own label. Hospira's One2One manufacturing services group generally does not manufacture active pharmaceutical ingredients, but offers a range of filling and finishing services in a variety of delivery systems.
Medication Management
Medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to Hospira pumps. These sets are used to deliver I.V. fluids and medications. Hospira also offers software maintenance agreements and other service offerings. Hospira's electronic drug delivery pumps include Hospira's general infusion system, Symbiq; the Plum A+ line of infusion pumps; Hospira's patient-controlled analgesia device, LifeCare PCA; the GemStar ambulatory infusion pump; and the Plum XLD infusion pump. Hospira offers the Hospira MedNet safety software system, which has been designed to enable hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. The Hospira MedNet system is standard in the Symbiq infusion system, and is also available as an additional feature for the Plum A+ line, and LifeCare PCA devices. Hospira also offers safety software with its Ge! mStar pum! p.
Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers' needlestick prevention initiatives. LifeShield CLAVE and LifeShield MicroCLAVE connectors are one-piece valves that directly connect syringes filled with medications to a patient's I.V. line without the use of needles. ICU Medical's CLAVE connectors are a component of administration sets sold by Hospira to its customers in the United States and select markets outside the United States.
The Company competes with Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi, Pfizer, Sandoz, Sanofi, Teva Pharmaceuticals, B. Braun Melsungen AG, CareFusion, Terumo, Actavis, Intas Pharmaceuticals, Ltd, Medac GmbH, Mylan Inc., Sun Pharmaceutical Industries, Ltd. and Aspen.
Advisors' Opinion:- [By Sean Williams]
And finally, would you be shocked if I said that medical-device and drug maker Hospira (NYSE: HSP ) ended the week on a high following a positive opinion from the CHMP on its biosimilar drug known as inflectra? The drug, which is targeted at treating rheumatoid arthritis, inflammatory bowel diseases, and plaque psoriasis, is a biosimilar of Johnson & Johnson's�blockbuster Remicade, which generates $6 billion in annual sales. Assuming Hospira can gain approval for inflectra (which appears likely, since the EMA often follows the advice of its panel), it could garner a big chunk of J&J's sales in the EU.
- [By Holly LaFon]
A few weaker sectors lagged the broad market advance. The energy, telecommunication services, and utilities groups gained ground but at a slower pace than most other S&P 500 sectors. Hess was a welcome exception in energy. Most of our investments in the lagging sectors moved higher but trailed the broad market. Our most disappointing energy holdings shared a common theme: exposure to the mining industry. As concerns about the pace of global economic growth intensified, particularly in emerging markets like China, our positions in Cliffs Natural Resources, Newmont Mining, and Joy Global were negatively affected. Fortunately, these composed relatively small positions in the portfolio. The Major Portfolio Changes table on page 8 shows the stocks in which we were active buyers and sellers during the first half of the year. We initiated positions in Apple (AAPL), Joy Global (JOY), Hospira (HSP), and Western Union (WU), all of which had stumbled in the eyes of investors, resulting in sharply falling share prices before we decided to invest in them. Consequently, the companies' stock valuations became more attractive to us. We normally favor companies whose share prices have declined because of cyclical worries, sector concerns, or company-specific issues. When a stock falls in value, its price/earnings ratio usually declines while its dividend yield increases, characteristics we look for as value investors. The strategy can be rewarding as long as the company's fundamentals are still sound.
- [By Holly LaFon] ra is the world�� largest producer of specialty generic injectable pharmaceuticals, and is a leading provider of contract manufacturing services to proprietary pharmaceutical and biotechnology companies for producing injectable pharmaceuticals.
Hospira�� share price had been falling gradually since its high of about $58 in April 2011, and began trading under $30 by mid-October. Owens, who held the stock since before 2008, had been selling shares as the price went up. In the fourth quarter of 2011, when the price fell to an average of $31.50, he bought 1 million shares, increasing his position by more than 91%. He now owns 2,095,070.
The October drop was due in large part to disappointing fourth-quarter earnings reported on October 26. The company�� diluted earnings per share fell to a loss of $(0.54), compared to $0.42 in the fourth quarter of 2010. The results were impacted by ��evelopments related to our quality-improvement initiatives,��according to the company�� CEO, F. Michael Ball. Diluted earnings per share for the nine months ended Sept. 30, 2011, were $1.21, down 31% from $1.75 in the first nine months of 2010.
Sales increased 2.9% to $977 million, compared to $949 million in the fourth quarter of 2010, mainly due to continued strong U.S. sales of the company�� oncolytic docetaxel product, but partially offset by the impact of quality actions in response to an FDA 2010 warning letter and subsequent observations related to the company�� manufacturing facility in Rocky Mount, N.C., and device quality and supply-related issues.
The company announced on October 18 that sales and earnings per share would be lower than anticipated due to actions they had to take to improve quality at the plant which caused a slowdown of production.
CVS Caremark (CVS)
CVS/Caremark is the nation's premier integrated pharmacy services provider, combining one of the nation's leading pharmaceutical services companies with the cou
- [By Ben Levisohn]
That decision has helped make Allergan the top performing pharmaceutical stock in the S&P 500. Its shares have gained 4.3% to $108.18, today at 2:32 p.m., besting Merck’s (MRK) 1.2% rise to $49.36, Mylan’s (MYL) 1.1% advance to $42.98, Hospira’s (HSP) 0.7% increase to $41.34 and Eli Lily’s (LLY) 0.6% rise to $50.42.
5 Best Net Payout Yield Stocks To Invest In Right Now: Powershares Buyback Achiever Portfolio (PKW)
PowerShares Buyback Achievers Portfolio (Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Share BuyBack Achievers Index (the Index). The Index is designed to track the performance of companies that meet the requirements to be classified as BuyBack Achievers. To become eligible for inclusion in the Index, a company must be incorporated in the United States, trade on the NYSE, the AMEX or the NASDAQ, and must have repurchased at least 5% or more of its outstanding shares for the trailing 12 months. The Index consists of stocks of companies selected by Mergent, Inc. (the Index Provider) pursuant to its own selection methodology. The Fund�� investment advisor is PowerShares Capital Management LLC.
The Index is rebalanced on the last trading date of April, July and October based on the constituents��modified market capitalizations as of the last trading day in March, June and September, respectively. The Fund generally will invest in the stocks comprising the Index in proportion to their weightings in the Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate the performance of the Index.
Advisors' Opinion:- [By John Waggoner]
The past five years, the PowerShares Buyback Achievers fund (ticker: PKW), has beaten the SPDR S&P 500 ETF trust by 3.91 percentage points a year, according to Morningstar, the Chicago investment trackers. So far this year, however, the fund has lagged behind the index by 2.28 percentage points ��a sign that Wall Street may be getting less impressed by buybacks.
- [By Roadmap2Retire] href="http://roadmap2retire.com/wp-content/uploads/2014/09/buybacks.jpg">
Stock Buybacks
One company that has resorted to financial engineering for quarter after quarter is International Business Machines Corp (IBM) ���nd it's only a matter of time before patience runs out. The company has seen declining revenues and cash holdings, while debt has continued to pile up. The company has been squeaking out quarters resorting to layoffs to keep the shareholders happy - and for the sake of the IBM shareholders, I hope management changes this path that they are heading down on.
On the other hand, General Electric (GE), with all the cash available, has been investing heavily in growing its business. GE is cutting losing business segments that are not lucrative anymore such as the appliance business, which it sold to Electrolux for $3.3B recently, and spun-off Synchrony Financial (SYF) ��its retail finance arm. Instead, GE is now returning to its industrial roots and expanding into new horizons such as oil & gas exploration and pipeline infrastructure tech, green energy investments such as wind, solar and fuel cells etc. These are lucrative businesses and I fully support the management in their decision as a shareholder. Note that GE, like others, has a share repurchase plan ��especially in 2013, GE has bought a lot of its own shares after selling its stake in NBC.
A plethora of companies have a history of buying at highs and selling at lows. This goes against any logic when it comes to good financial sense. When times are good and companies are flush with cash, like the current environment, the management authorizes buying its own shares and during lean times - after market crashes and/or recessions, the companies cut back on share repurchases. So, the question for the retail investors is: Instead of investing or paying down debt, if the company is buying its own shares and the insiders are selling, should you be buying? It comes as no
- [By Marvin Appel, CEO and Founder, Appel Asset Management Corporation]
Buyback Achievers ETF (PKW)
The stocks in this ETF are those that have repurchased at least 5% of their shares in the 12 months preceding the reconstitution of the index every January. 200 stocks currently qualify. (They are weighted by market capitalization.)
- [By Elliott Gue]
Just check out the PowerShares Buyback Achievers ETF (NYSE: PKW), which invests in companies that have bought back at least 5% of their shares outstanding during the prior 12 months. This ETF has more than doubled the returns of the S&P 500 over the past five years.
No comments:
Post a Comment